



RS 504393

Catalog No: tcsc0851

| (| 4 | | | | | | |
|---|---|---|---|---|---|---|---|
| • | 5 | i | 2 | Z | • | е | 1 |
| | | | | | | | |

Available Sizes

Size: 5mg

Size: 10mg

Size: 25mg

Size: 50mg



Specifications

CAS No:

300816-15-3

Formula:

 $C_{25}H_{27}N_3O_3$

Pathway:

Immunology/Inflammation;GPCR/G Protein

Target:

CCR;CCR

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 10 mg/mL (23.95 mM)

Observed Molecular Weight:

417.5

Product Description

RS 504393 is a selective **CCR2** chemokine receptor antagonist (IC_{50} values are 89 nM and > 100 μ M for inhibition of human





recombinant CCR2 and CCR1 receptors respectively).

IC50 & Target: IC50: 89 nM (CCR2)^[5]

In Vitro: RS 504393 inhibits the MCP-1-induced chemotaxis with an IC₅₀ of 330 nM. RS 504393 treatment suppresses allergen induced β -hexosaminidase release significantly. Without allergen priming, MCP-1 induces mast cell degranulation, which is completely suppressed by RS 504393^[4].

In Vivo: RS504393 (0.3-3 μ g) with CCL2 progressively blocks thermal hyperalgesia dose-dependently in mice^[1]. RS 504393 (5 mg/kg, i.v.) supresses the elevated numbers of leukocytes and increased total protein content in BALF induced by The LPS. RS504393 significantly down regulates the LPS-induced elevation of IL-1 β , PAI-1 mRNA and protein expressions. RS504393 significantly suppresses induced lung edema, protein-rich fluid, polymorphonuclear accumulation and bronchial wall thickening induced by LPS^[2]. RS-504393 significantly reduces renal pathology, especially the extensive interstitial fibrosis mediated by decrease in type I collagen synthesis in a UUO model^[3].

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!